Business Description
Pliant Therapeutics is a clinical-stage company developing medicines that target proteins called integrins, which play a key role in cancer progression. Its most advanced treatment, PLN-101095, is a tablet taken by mouth that blocks two specific integrins at once and is currently being tested in patients with solid tumors. The company also maintains a library of more than 15,000 integrin-binding compounds to support the discovery of future treatments. Founded in 2015, Pliant is based in South San Francisco, California.
